论文部分内容阅读
目的:探讨A型肉病毒素(dysport)治疗睑肌痉挛的长期疗效及安全性。方法:回顾性分析46例原发性睑肌痉挛患者于第1、3、5年接受dysport注射的剂量、起效时间、疗效持续时间、症状改善率不良反应。结果:46例患者第1、3、5年中位症状改善率分别为90%、85%及80%,治疗5年后仍有93.48%的患者改善率50%,且疗效持续8周以上。第1、3、5年起效时间分别为4、5和7 d,有延长趋势;疗效持续时间稳定维持在12周;治疗剂量略有下降,但无显著性差异。主要不良反应为睑下垂、疼痛烧灼感、复视及局部血肿,1周内自行消失,无过敏及全身不良反应。结论:dysport局部注射治疗睑肌痉挛安全,疗效持久,能最大程度地改善局部痉挛症状,可能成为治疗睑肌痉挛的首选方法。
Objective: To investigate the long-term efficacy and safety of type A meconium to treat blepharospasm spasm. Methods: A retrospective analysis of 46 patients with primary blepharospasm patients in the 1st, 3rd, 5th dose of dysport injection, onset time, duration of treatment, the rate of improvement of adverse reactions. Results: The median improvement rates of the first, third, and fifth years in 46 patients were 90%, 85% and 80% respectively. After 5 years, 93.48% of the patients had a 50% improvement rate and the effect lasted for more than 8 weeks. The first, third and fifth years of onset time were 4, 5 and 7 d, respectively, with an extension trend; efficacy duration remained stable at 12 weeks; treatment dose decreased slightly, but no significant difference. The main adverse reactions were ptosis, pain burning sensation, diplopia and local hematoma, one week disappear on their own, no allergies and systemic adverse reactions. Conclusion: Local injection of dysport for the treatment of levator muscle spasm is safe and long-lasting, which can improve the symptoms of local spasticity to the maximum extent and may be the preferred method of treating blepharospasm.